Show simple item record

dc.contributor.authorCoakley, M
dc.contributor.authorGarcia-Murillas, I
dc.contributor.authorTurner, NC
dc.date.accessioned2019-05-07T11:25:03Z
dc.date.issued2019-10
dc.identifier.citationClinical cancer research : an official journal of the American Association for Cancer Research, 2019, 25 (20), pp. 6026 - 6034
dc.identifier.issn1078-0432
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/3221
dc.identifier.eissn1557-3265
dc.identifier.doi10.1158/1078-0432.ccr-19-0152
dc.description.abstractAdvances in diagnosis and treatment have resulted in a high rate of survival for many patients with early-stage cancers. However, identifying who is at ongoing risk of relapse remains of high priority to direct subsequent adjuvant therapy. Multiple recent retrospective studies have shown that detection of tumor-derived materials in blood, in particular with circulating tumor DNA (ctDNA) analysis, can identify patients with residual disease before clinical or radiological evidence of metastatic disease, anticipating relapse with relatively high sensitivity and high specificity. We discuss how these emerging technologies are defining new subgroups of patients with "Molecular Residual Disease" and "Molecular Relapse." We outline how novel clinical trials in the adjuvant setting designed for these new subgroups of patients may improve selection for adjuvant therapies, and provide new surrogate endpoints that may allow for early registration of adjuvant therapies and novel clinical trial designs in the adjuvant setting. We discuss the current limitations of these techniques and the routes to clinical implementation.
dc.formatPrint-Electronic
dc.format.extent6026 - 6034
dc.languageeng
dc.language.isoeng
dc.rights.urihttps://www.rioxx.net/licenses/all-rights-reserved
dc.subjectHumans
dc.subjectNeoplasms
dc.subjectNeoplasm Recurrence, Local
dc.subjectNeoplasm, Residual
dc.subjectAntineoplastic Agents
dc.subjectPrognosis
dc.subjectTreatment Outcome
dc.subjectChemotherapy, Adjuvant
dc.subjectRisk Assessment
dc.subjectResearch Design
dc.subjectClinical Trials as Topic
dc.subjectBiomarkers, Tumor
dc.subjectCirculating Tumor DNA
dc.titleMolecular Residual Disease and Adjuvant Trial Design in Solid Tumors.
dc.typeJournal Article
dcterms.dateAccepted2019-05-09
rioxxterms.versionofrecord10.1158/1078-0432.ccr-19-0152
rioxxterms.licenseref.urihttps://www.rioxx.net/licenses/all-rights-reserved
rioxxterms.licenseref.startdate2019-10
rioxxterms.typeJournal Article/Review
dc.relation.isPartOfClinical cancer research : an official journal of the American Association for Cancer Research
pubs.issue20
pubs.notes12 months
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Breast Cancer Research
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Breast Cancer Research/Molecular Oncology
pubs.organisational-group/ICR/Students
pubs.organisational-group/ICR/Students/PhD and MPhil
pubs.organisational-group/ICR/Students/PhD and MPhil/18/19 Starting Cohort
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Breast Cancer Research
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Breast Cancer Research/Molecular Oncology
pubs.organisational-group/ICR/Students
pubs.organisational-group/ICR/Students/PhD and MPhil
pubs.organisational-group/ICR/Students/PhD and MPhil/18/19 Starting Cohort
pubs.publication-statusPublished
pubs.volume25
pubs.embargo.terms12 months
icr.researchteamMolecular Oncologyen_US
dc.contributor.icrauthorCoakley, Mariaen
dc.contributor.icrauthorTurner, Nicholasen
dc.contributor.icrauthorGarcia-Murillas, Isaacen


Files in this item

Thumbnail

This item appears in the following collection(s)

Show simple item record